Måndag 11 Maj | 12:03:06 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-08-31 07:00 Kvartalsrapport 2026-Q2
2026-05-11 N/A X-dag ordinarie utdelning CRNA 0.00 NOK
2026-05-08 - Årsstämma
2026-04-15 - Bokslutskommuniké 2025
2026-01-12 - Extra Bolagsstämma 2026
2025-08-28 - Kvartalsrapport 2025-Q2
2025-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2025-06-05 - Årsstämma
2025-04-10 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-06-19 - Årsstämma
2024-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2024-04-25 - Bokslutskommuniké 2023
2023-10-04 - Split CRNA 30:1
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-22 - Årsstämma
2023-04-21 - X-dag ordinarie utdelning CRNA 0.00 NOK
2023-03-09 - Extra Bolagsstämma 2023
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-20 - Årsstämma
2022-04-07 - X-dag ordinarie utdelning CRNA 0.00 NOK
2022-02-17 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-03-18 - X-dag ordinarie utdelning CRNA 0.00 NOK
2021-03-17 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-30 - X-dag ordinarie utdelning CRNA 0.00 NOK
2020-04-29 - Årsstämma
2020-03-11 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-09 - Kvartalsrapport 2019-Q1
2019-04-10 - X-dag ordinarie utdelning CRNA 0.00 NOK
2019-04-09 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-03 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning CRNA 0.00 NOK
2018-04-11 - Årsstämma
2018-02-15 - Bokslutskommuniké 2017
2017-11-16 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-04-25 - Kvartalsrapport 2017-Q1
2017-04-05 - Årsstämma
2017-02-16 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-14 - X-dag ordinarie utdelning CRNA 0.00 NOK
2016-04-13 - Årsstämma
2015-06-23 - X-dag ordinarie utdelning CRNA 0.00 NOK
2015-06-22 - Årsstämma

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriBioteknik
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-05-11 11:08:00

Oslo, 11 May 2026: Reference is made to the annual general meeting of Circio Holding ASA (the “Company”) on 8 May 2026 (the “AGM”) where the election of members to the board of directors was made according to the proposal by the nomination committee.

At the AGM, the board of directors was authorized to extend the Company’s restricted stock unit (“RSU”) program and to issue RSUs to directors of the board as an alternative to cash compensation. The RSUs are non-transferable and each RSU gives the right and obligation to acquire one share in the Company at a price of NOK 0.60 per share (corresponding to the nominal value of the shares) subject to satisfaction of the applicable vesting conditions.

If the board members choose to receive the board remuneration in RSUs they must elect to either (i) receive 100% of the compensation in RSUs, (ii) receive 1/3 of the compensation in cash and 2/3 in RSUs, or (iii) receive 2/3 of the compensation in cash and 1/3 in RSUs.

The number of RSUs is calculated on the basis of a board remuneration of NOK 575 000 for the chairperson of the board, NOK 350,000 for other board members and 180,000 for deputy members of the board, divided by the market price of the Company’s shares calculated as the volume weighted average share price for the 10 trading days prior to the AGM, on May 8 2026, being NOK 8.7966 per share.

  • Damian Marron, chairman of the board of directors, has resolved to receive 1/3 of the board remuneration, as determined by the Company’s annual general meeting in 2026, in the form of RSUs and the board of directors has resolved to issue 21,789 RSUs to Damian Marron. Damian Marron holds 21,789 RSUs, no options and 311,863 shares in the Company.
  • Diane Mellett, member of the board of directors, has resolved to receive 1/3 of the board remuneration, as determined by the Company’s annual general meeting in 2026, in the form of RSUs and the board of directors has resolved to issue 13,263 RSUs to Diane Mellett. Diane Mellett holds 25,933 RSUs, no options and 262,258 shares in the Company.
  • Thomas Falck, member of the board of directors, has resolved to receive 1/3 of the board remuneration, as determined by the Company’s annual general meeting in 2026, in the form of RSUs and the board of directors has resolved to issue 13,263 RSUs to Thomas Falck. Thomas Falck holds 13,263 RSUs, no options and 415,535 shares (partly through Sølen AS) in the Company.

Please see the attached notifications of trade for information regarding the issuance of RSUs to the primary insiders.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.